GIP receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-05. Anything still debated is marked as such rather than presented as settled.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
== Mechanisms of membrane translocation == Cell-penetrating peptides are of different sizes, amino acid sequences, and charges, but all CPPs have the ability to translocate the plasma membrane and facilitate the delivery of various molecular cargoes to the cytoplasm or an organelle. No real consensus explains the translocation mechanism, but candidates can be classified into three mechanisms: direct penetration in the membrane, endocytosis-mediated entry, and translocation through a transitory structure. CPP transduction is an area of ongoing research. Cell-penetrating peptides (CPP) are able to transport different types of cargo molecules across plasma membrane; thus, they act as molecular delivery vehicles. They have numerous applications in medicine as drug delivery agents in the treatment of different diseases including cancer and virus inhibitors, as well as contrast agents for cell labeling. Examples of the latter include acting as a carrier for GFP, MRI contrast agents, or quantum dots.
=== Neuroendocrine === KOR agonists increase serum prolactin levels by tonic inhibition of hypothalamic dopaminergic systems. This response occurs following administration of both centrally penetrating and peripherally restricted KOR agonists. Activation of KOR produce diuretic effects through negative regulation of vasopressin, also known as antidiuretic hormone (ADH). This water diuresis is characterized by increased urine volume and decreased urine osmolality without prominent alterations in electrolyte excretion. Both centrally and peripherally acting KOR agonists promote diuresis through mechanisms including decreased antidiuretic hormone secretion from the hypothalamus and posterior pituitary, reduced renal responsiveness to antidiuretic hormone, and modulation of renal sympathetic nerve activity. KOR signaling in renal tissue may also modulate responses to metabolic stress and induce pathophysiological processes in kidney disease. Activation of the receptor increases adrenocorticotropic hormone (ACTH) and cortisol levels in humans and non-human primates through activation of the hypothalamic-pituitary-adrenal axis (HPA). Administration of the selective agonist U50,488 dose-dependently stimulates ACTH and cortisol release, an effect specific to KOR activation and not observed following μ-opioid (MOR) or δ-opioid receptor (DOR) stimulation. KOR exhibits coexpression with oxytocin and vasopressin in the paraventricular nucleus (PVN) and supraoptic nucleus (SON) of the hypothalamus.
To increase the potency they attached a phenolic group to the aromatic ring, N-methyl-trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine. That structure was used to design and develop other opioid receptors antagonists such as alvimopan. Alvimopan was approved later in 2008 for in-hospital use to increase the gastrointestinal function following a partial large or small bowel resection with primary anastomosis. Naloxegol was approved in September 2014 and naldemedine in March 2017, both for the treatment of OIC in adult patients with chronic cancer.
==== International Baccalaureate ==== The International Baccalaureate (IB) Diploma Magnet Program is a course of study. The mission of the program is to develop inquiring, knowledgeable, and caring young people who help to create a better, more peaceful world through intercultural understanding and respect. The IB program offers many benefits to its participants, such as: higher university and college acceptance rates for IB graduates; increased scholarship and grant opportunities; a college-level academic program that transitions students to university and college standards; and teacher development using IB strategies. Locations:
Sources: en.wikipedia.org
=== Terrestrial === The composition of terrestrial species on the Kuril islands is dominated by Asian mainland taxa via migration from Hokkaido and Sakhalin Islands and by Kamchatkan taxa from the North. While highly diverse, there is a relatively low level of endemism on a species level. The WWF divides the Kuril Islands into two ecoregions. The southern Kurils, along with southwestern Sakhalin, comprise the South Sakhalin-Kurile mixed forests ecoregion. The northern islands are part of the Kamchatka-Kurile meadows and sparse forests, a larger ecoregion that extends onto the Kamchatka Peninsula and Commander Islands. The Miyabe Line dividing the differing sets of predominant plants of the Kurils corresponds to the Vries Strait between Iturup and Urup. Because of the generally smaller size and isolation of the central islands, few major terrestrial mammals have colonized these, though red and Arctic foxes were introduced for the sake of the fur trade in the 1880s. The bulk of the terrestrial mammal biomass is taken up by rodents, many introduced in historical times. The largest southernmost and northernmost islands are inhabited by brown bear, foxes, and martens. Leopards once inhabited the islands. Some species of deer are found on the more southerly islands. It is claimed that a wild cat, the Kurilian Bobtail, originates from the Kuril Islands. The bobtail is due to the mutation of a dominant gene. The cat has been domesticated and exported to nearby Russia and bred there, becoming a popular domestic cat.
Source 2 has also been used for Valve's Artifact and Dota Underlords, with the engine later being supported on Android and iOS for the latter. The engine also supports the creation of games in virtual reality, being used in SteamVR Home, the Robot Repair tech demo within The Lab, and Half-Life: Alyx. Source 2 tools made specifically for creating content for Half-Life: Alyx were released in May 2020.
=== Vesicle trafficking === This particular domain, the Vitellogenin lipid transport domain, is also found in the Microsomal triglyceride transfer protein (MTTP) and in Apolipoprotein B. It aids cell trafficking and export of cargo.
Pedro Cuatrecasas (27 September 1936 – 19 March 2025) was a Spanish-born American biochemist and academic who was an adjunct professor of Pharmacology & Medicine at the University of California San Diego.
1991: Invercargill re-proclaimed a city. 1992: Nelson-Marlborough Regional Council abolished by a Local Government Amendment Act. Of its territorial authorities, the Kaikōura District was transferred to the Canterbury Region, and Nelson City and Tasman and Marlborough districts became unitary authorities. 1995: The Chatham Islands County was dissolved and reconstituted by an Act of Parliament as the "Chatham Islands Territory", with powers similar to those of territorial authorities and some functions similar to those of a regional council. 2004: Tauranga became a city again on 1 March. 2006: The Banks Peninsula District merged into Christchurch as a result of a 2005 referendum. 2010: Auckland Council, a unitary authority, replaced seven local councils and the regional council. Reports on completed reorganisation proposals since 1999 are available on the Local Government Commission's site (link below).
Sources: en.wikipedia.org
Angiotensin-converting-enzyme inhibitors (ACE inhibitors) are a class of medication used primarily for the treatment of cardiovascular and kidney diseases. This class of medicine works by causing relaxation of blood vessels as well as a decrease in blood volume, which leads to lower blood pressure and decreased oxygen demand from the heart. ACE inhibitors inhibit the activity of angiotensin-converting enzyme, an important component of the renin–angiotensin system which converts angiotensin I to angiotensin II, and hydrolyzes bradykinin. Therefore, ACE inhibitors decrease the formation of angiotensin II, a vasoconstrictor, and increase the level of bradykinin, a peptide vasodilator. This combination is synergistic in lowering blood pressure. As a result of inhibiting the ACE enzyme in the bradykinin system, the ACE inhibitor drugs allow for increased levels of bradykinin which would normally be degraded. Bradykinin produces prostaglandin. This mechanism can explain the two most common side effects seen with ACE Inhibitors: angioedema and cough.
=== Oxidation and inflammation === Free radicals and pro-oxidants in cigarettes damage blood vessels and oxidize LDL cholesterol. Only oxidized LDL cholesterol is taken-up by macrophages, which become foam cells, leading to atherosclerotic plaques. Cigarette smoke increases proinflammatory cytokines in the bloodstream, causing atherosclerosis. The pro-oxidative state also leads to endothelial dysfunction, which is another important cause of atherosclerosis.
A transaminase converts the oxaloacetate to aspartate for transport back across the membrane and into the intermembrane space. In oxidative phosphorylation, the passage of electrons from NADH and FADH2 through the electron transport chain releases the energy to pump protons out of the mitochondrial matrix and into the intermembrane space. This pumping generates a proton motive force that is the net effect of a pH gradient and an electric potential gradient across the inner mitochondrial membrane. Flow of protons down this potential gradient – that is, from the intermembrane space to the matrix – yields ATP by ATP synthase. Three ATP are produced per turn. Although oxygen consumption appears fundamental for the maintenance of the proton motive force, in the event of oxygen shortage (hypoxia), intracellular acidosis (mediated by enhanced glycolytic rates and ATP hydrolysis), contributes to mitochondrial membrane potential and directly drives ATP synthesis. Most of the ATP synthesized in the mitochondria will be used for cellular processes in the cytosol; thus it must be exported from its site of synthesis in the mitochondrial matrix. ATP outward movement is favored by the inner mitochondrial membrane's electrochemical potential because the cytosol has a relatively positive charge compared to the relatively negative matrix. For every ATP transported out, it costs 1 H+. Producing one ATP costs about 3 H+. Therefore, making and exporting one ATP requires 4H+.
The fifth generation Familia (BD), first shown on 2 June 1980, was entirely new – it was Mazda's first front-engine, front-wheel-drive subcompact car, and was available as a hatchback and saloon. It was developed with input from Ford, which in 1979 had acquired a stake in the Japanese manufacturer, and had a twin called the Ford Laser (and Ford Meteor, for its four-door saloon model in Australia). At its introduction in 1980, it won the first Car of the Year Japan Award. The new Mazda E engine-series, loosely based on the preceding PC/TC/UC series, was developed expressly for the BD and was offered in three different displacements. The smallest 1.1-litre E1 unit was reserved for certain export markets where the tax structures suited it. Chassis codes were BD1011/BD1031/BD1051 depending on the engine installed. Engines:
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.